Results 121 to 130 of about 908,554 (203)

ERK signaling promotes resistance to TRK kinase inhibition in NTRK fusion-driven glioma mouse models

Cell Reports
Summary: Pediatric-type high-grade gliomas frequently harbor gene fusions involving receptor tyrosine kinase genes, including neurotrophic tyrosine kinase receptor (NTRK) fusions.
Sebastian Schmid, Zachary R. Russell, Alex Shimura Yamashita, Madeline E. West, Abigail G. Parrish, Julia Walker, Dmytro Rudoy, James Z. Yan, David C. Quist, Betemariyam N. Gessesse, Neriah Alvinez, Kimberly D. Hill, Larry W. Anderson, Patrick J. Cimino, Debra K. Kumasaka, Ralph E. Parchment, Eric C. Holland, Frank Szulzewsky   +17 more
doaj   +1 more source

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG) [PDF]

, 2022
BACKGROUND: Entrectinib is a TRKA/B/C, ROS1, ALK tyrosine kinase inhibitor approved for the treatment of adults and children aged ≥12 years with NTRK fusion-positive solid tumors and adults with ROS1 fusion-positive non-small-cell lung cancer.
Armstrong, Amy E, Desai, Ami V, et al.,, Gauvain, Karen   +3 more
core   +1 more source

The Occurrence of Gene Fusions in Thyroid Lesions and the Relation With Chronic Lymphocytic Thyroiditis

Pathology International, Volume 76, Issue 1, January 2026.
We identified both known and novel gene fusions in thyroid neoplasia, including several previously reported only in nonthyroid malignancies. Gene fusion–positive tumors were significantly (p < 0.001, annotated as ***) associated with florid chronic lymphocytic thyroiditis, unlike tumors driven by somatic mutations or copy number variations.
Maaia Margo Jentus, Tom van Wezel, Dina Ruano, Marieke Snel, Abbey Schepers, Stijn Crobach, Hans Morreau   +6 more
wiley   +1 more source

Clinical characteristics and treatment patterns of patients with NTRK fusion-positive solid tumors: A multisite cohort study at US academic cancer centers. [PDF]

BACKGROUND: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are rare oncogenic drivers prevalent in 0.3% of solid tumors. They are most common in salivary gland cancer (2.6%), thyroid cancer (1.6%), and soft-tissue sarcoma (1.5%).
Appukkuttan, Sreevalsa, Au, Trang, Brixner, Diana, Federman, Noah, Griswold, Cassia, Hejazi, Andre, Hocum, Brian, Ko, Gilbert, Kong, Sheldon, Malhotra, Jyoti, Schabath, Matthew, Stenehjem, David, Thompson, Jonathan, Warnock, Neil, Willis, Connor   +14 more
core   +1 more source

A CLIP on the Ear: Spitz Melanocytoma Harbouring a CLIP2-BRAF Gene Fusion

Case Reports in Dermatological Medicine, Volume 2026, Issue 1, 2026.
Spitzoid lesions represent one of the most challenging areas in melanocytic pathology. Many such lesions are characterised by key gene alterations including ALK, ROS and NTRK fusions. BRAF mutations are generally considered incompatible with the diagnosis of Spitz tumours. Here, we present the case of a spitzoid melanocytoma harbouring a rare BRAF gene
Karwan A. Moutasim, Mohammed Atweh, Jeffery M. Theaker, Pedro Rodriguez Jimenez   +3 more
wiley   +1 more source

Radioresistant but Alectinib‐Responsive Isolated Intramedullary ALK‐Positive Histiocytosis

Case Reports in Hematology, Volume 2026, Issue 1, 2026.
A 56‐year‐old woman with a history of C4–C5 myelomeningocele repair as a newborn and cervical syringomyelia presented with one week of rapidly worsening bilateral lower extremity weakness and numbness, saddle anesthesia, and bladder incontinence. MRI of the entire spine revealed a 1.5 × 0.5 cm homogenously enhancing intramedullary lesion at T7–T8 with ...
Joshua Van Allen, David Raggay, Brendan Killory, Joseph DiGiuseppe, Mark Dailey, Carlos Cruz-Montecinos   +5 more
wiley   +1 more source

Comparison of NTRK fusion detection methods in microsatellite-instability-high metastatic colorectal cancer [PDF]

, 2023
Tropomyosin receptor kinase (TRK) inhibitors have been approved for metastatic solid tumors harboring NTRK fusions, but the detection of NTRK fusions is challenging. International guidelines recommend pan-TRK immunohistochemistry (IHC) screening followed
Bol, Guus M, Brosens, Lodewijk A A, de Leng, Wendy W, Feitsma, Harma, Fijneman, Remond J A, Koopman, Miriam, Laclé, Miangela M, Schraa, Suzanna J, Stelloo, Ellen, Swennenhuis, Joost F, Vink, Geraldine R   +10 more
core  

Neurotrophic tyrosine receptor kinase gene fusions in adult and pediatric patients with solid tumors: a clinicogenomic biobank and record linkage study of expression frequency and patient characteristics from Finland

Acta Oncologica
Background: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers. Using the Auria Biobank in Finland, we aimed to identify and characterize patients with these gene fusions, and describe their clinical and tumor ...
Wei Zhang, Arndt A. Schmitz, Roosa E. Kallionpää, Merja Perälä, Niina Pitkänen, Mikko Tukiainen, Erika Alanne, Korinna Jöhrens, Renate Schulze-Rath, Bahman Farahmand, Jihong Zong   +10 more
doaj   +1 more source

NTRK gene fusion testing and management in lung cancer

Cancer Treatment Reviews
Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are recurrent oncogenic drivers found in a variety of solid tumours, including lung cancer. Several tropomyosin receptor kinase (TRK) inhibitors have been developed to treat tumours with NTRK gene fusions.
Repetto, M, Chiara Garassino, M, Loong, HH, Lopez-Rios, F, Mok, T, Peters, S, Planchard, D, Popat, S, Rudzinski, ER, Drilon, A, Zhou, C   +10 more
openaire   +4 more sources

NTRK Gene Expression in Non-Small-Cell Lung Cancer

Journal of Respiration
Background/Objectives: Since the discovery of oncogenic neurotrophic receptor tyrosine kinase (NTRK) gene fusions in colorectal cancer in 1986, their understanding has evolved, particularly in non-small-cell lung cancer (NSCLC) over the past five years ...
Jair Gutierrez-Herrera, M. Angeles Montero-Fernandez, Georgia Kokaraki, Luigi De Petris, Raul Maia Falcão, Manuel Molina-Centelles, Ricardo Guijarro, Simon Ekman, Cristian Ortiz-Villalón   +8 more
doaj   +1 more source